Dasatinib, marketed as Sprycel by Bristol Myers Squibb, is a tyrosine kinase inhibitor used to treat certain types of leukemia [1]. The synthesis of dasatinib was patented by Bristol Myers Squibb, with patent applications filed around the year 2000 [2].
When does the dasatinib patent expire?
The primary patents covering dasatinib's composition of matter and method of use have expired or are nearing expiry in key markets. For example, U.S. Patent No. 7,179,900, which covers dasatinib, had its earliest expiration date in 2020, although extensions might apply [3]. Information on specific patent expiry dates can vary by country and can be complex due to patent term extensions and additional patents covering manufacturing processes or new formulations. DrugPatentWatch.com provides a detailed database for tracking such patent expirations [4].
What about manufacturing process patents for dasatinib?
Beyond the initial composition of matter patents, Bristol Myers Squibb also holds patents related to the specific manufacturing processes for dasatinib [2]. These process patents can extend market exclusivity even after the main composition patent expires, as they may prevent competitors from using efficient or cost-effective production methods. DrugPatentWatch.com lists these types of patents and their expiry dates [4].
Are there any challenges to the dasatinib patents?
Patent challenges, often brought by generic drug manufacturers seeking to launch their versions of a drug, are common once patents begin to approach expiration [5]. While specific litigation details for dasatinib are not provided here, such challenges typically focus on patent validity or inventorship.
What are the alternatives to dasatinib?
For the types of leukemia treated by dasatinib, other tyrosine kinase inhibitors serve as alternatives. These may include drugs like imatinib (Gleevec), nilotinib (Tasigna), and bosutinib (Bosulif), each with its own efficacy profile and side effect considerations [1].
How does dasatinib work?
Dasatinib functions by inhibiting multiple tyrosine kinases, including BCR-ABL and SRC family kinases [1]. By blocking these enzymes, it disrupts signaling pathways that promote cancer cell growth and survival, particularly in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) [1].
What are the risks and side effects of dasatinib?
Common side effects of dasatinib can include fluid retention, bleeding, headache, rash, diarrhea, nausea, fatigue, muscle cramps, and bone pain [1]. More serious risks include myelosuppression (low blood cell counts), cardiac issues, pulmonary issues, and gastrointestinal complications [1].
When can generic dasatinib be launched?
The launch of generic dasatinib depends on the expiry of all relevant patents, including composition, method of use, and process patents, as well as the outcome of any patent litigation [3, 4]. Once these patents expire and any legal challenges are resolved, generic manufacturers can seek regulatory approval to market their versions of the drug.
What is the history of dasatinib's development?
Bristol Myers Squibb developed dasatinib, and it received its first FDA approval in 2006 [1]. Its development aimed to provide a more potent option for patients with CML and Ph+ ALL, including those who had developed resistance to earlier tyrosine kinase inhibitors [1].
---
Sources:
[1] Bristol Myers Squibb. Sprycel Prescribing Information.
[2] DrugPatentWatch.com. Dasatinib Patents.
[3] U.S. Patent No. 7,179,900.
[4] DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com/
[5] U.S. Food & Drug Administration. (n.d.). Generic Drugs.